Gynecological Malignancies: Clinical Trials

3 trials for Gynecological Malignancies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 1, Not yet recruiting 1, Recruiting 1
Phase 22Not yet recruiting 1, Recruiting 1

Follow Gynecological Malignancies: new trials by email Literature Review of Gynecological Malignancies trials Research Report on Gynecological Malignancies

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
9MW2821+other anticancer therapy - Gynecological Malignancies
Phase 1 / Phase 2Not yet recruitingMabwell (Shanghai) Bioscience Co., Ltd.2602025-04-152025-04-15
A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies
BL-M07D1 - Gynecological Malignancies
Phase 1 / Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.1582024-02-292026-10-23
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan - Cancer, Carcinoma
Phase 1CompletedAmgen1032009-01-012015-09-29

Narrower conditions

Carcinoma (1)  ·  Fallopian Tube Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)

Broader conditions

Adnexal Diseases (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Fallopian Tube Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Gonadal Disorders (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Neoplastic Processes (1)  ·  Ovarian Diseases (1)

Interventions

Topotecan (1)  ·  liposomal doxorubicin (1)  ·  trebananib (1)

Sponsors

Amgen (1)  ·  Mabwell (Shanghai) Bioscience Co., Ltd. (1)  ·  Sichuan Baili Pharmaceutical Co., Ltd. (1)

Countries

China (2)  ·  Australia (1)  ·  Belgium (1)  ·  United States (1)

Top investigators

Hanmei Lou, Professor (1)  ·  Lingying Wu, PHD (1)